Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sirius xm was upgraded by a Evercore this morning.
Haven't had a chance to read the full report yet. Thanks for the info. AMD long!
;) tomorrow should be a good day as long as it's not sell the news type of day! GLTA!
That's my same question and concern.
I believe they have. I just got a alert from seekingalpha beat EPS by .02 and beat revenue by .05
It's bounced off the first level of support this morning so let's hope it keeps heading back up today.
From the chairman's blog this morning.....
Onwards and Upwards: Building value from a solid foundation
The last few weeks have been very exciting for Amarantus. Since our initial Chairman’s Blog post on December 11th, 2012 we have achieved several important corporate milestones to set the stage for growth in 2013, including:
Publicly releasing groundbreaking efficacy data for our protein drug candidate MANF in a neurorestoration animal model of Parkinson’s disease, our lead therapeutic indication;
Acquiring 25 pieces of intellectual property from Power3 Medical Products, Inc. (“Power3”) related to the diagnosis of a number of neurodegenerative diseases and cancers. The transaction also included the buyout of our Parkinson’s disease license with Power3; and
Licensing a Phase 2-ready Alzheimer’s disease diagnostic blood test called LymPro to detect mild to moderate Alzheimer’s disease; a diagnostic category highly sought by Big Pharma
The fundamentals of the Company have continued to progress and this was validated last week when the Company attended two key conferences in San Francisco, where we met with research analysts, fund managers and pharmaceutical executives. This increase in awareness also comes with a significant increase in scrutiny as it relates to the manner in which our data sets are presented and our financing plans. Therefore, I will address some of these key areas here:
The data the Company released last week related to our MANF program in Parkinson’s disease is groundbreaking and first of its kind in the Parkinson’s space. Our Chief Scientific Officer, Dr. John Commissiong, presented the data at the OneMedForum 2013 Healthcare Conference, and showed a significant positive impact in every data category, thus supporting advancing MANF in both Investigational New Drug (“IND”)- enabling studies and human clinical studies. From an academic standpoint, the data produced represents a new ‘positive control’ for this model, heretofore changing the way these experiments are performed in academic labs throughout the world, with MANF likely becoming the new standard. As such, it is important for the experiments to be repeated in academia to get the most efficacious dosing regimen in the model so that new therapies can be compared against the budding new standard, MANF.
While we are constantly evaluating options as it relates to our financial structure, including grants, partnerships, joint ventures, collaborations, and securities offerings, the Company has not made any specific decisions as to its next steps in this regard, despite misleading articles written on certain websites. The Company believes these misleading statements may be intended to dampen market enthusiasm, while enhancing trading strategies for certain trading groups. We are evaluating legal options as it relates to these misleading statements and the Company will continue to work to defend shareholder value. Concurrently with this, we will be taking stronger action against the unauthorized listing of our common stock on the Berlin Stock Exchange, as the Company believes the misleading articles may be related to this listing.
As MANF continues forward in its development, the Company expects to build the most accretive value in the near-term from its diagnostic assets. As previously discussed, the Company is now in an excellent negotiating position with potential partners and investors interested in advancing our diagnostic candidates forward on favorable terms so we can devote the majority of our internal resources to our MANF programs in Parkinson’s disease, Traumatic Brain Injury, Cardiac Ischemia and the evaluation of certain orphan indications. We will update the marketplace regarding our diagnostic assets and plans for their continued development in the near future.
In closing, the future has never looked brighter for Amarantus. We have unambiguous data supporting MANF’s further development in our lead Parkinson’s disease indication, we now have rights to seven diagnostic blood tests in significant markets, and our MANF asset continues to make progress in secondary indications. We are looking forward to an exciting 2013 for the Company and its shareholders.
I thank you for taking the time to read this letter and looking forward to communicating with you in the future.
Sincerely,
Gerald E. Commissiong
President & Chief Executive Officer
5.5 cent spike upwards! Yeah I think so too! :)
Here is part of it.
As evidenced by the recent licensing of a breakthrough in Alzheimer’s diagnostics by pending JV partner Amarantus BioScience, Inc. (AMBS), a blood test for the terrible neurological disease that has severely impacted the lives of some 5.4M Americans and counting (that’s one in eight out of a burgeoning boomer population, costing upwards of $200B in the U.S. alone in 2012). This new, ingenious diagnostic framework, the LymPro Alzheimer’s Disease Diagnostic Blood Test (LymPro) by Memory Dx, LLC, promises to become an indispensible tool in the clinical trial tool belt for Alzheimer’s.
A similar JV framework was arrived at previously for AMBS’s Parkinson’s disease and traumatic brain/nervous system injury diagnostic offering, NuroPro, designed as an early warning Parkinson’s Diagnostic Blood Test and a disease-modifying protein drug candidate to accompany the early warning system. Amarantus landed $1.1M in financing in November on the strength of their balance sheet and pipeline potential alone.
The AMBS relationship is a perfect example of the cunning strategic savvy already demonstrated by RBCC, which has clearly spotted the market cap potential in teaming up with this sort of company, who can also really drop the hammer when it comes to securing vital IP infrastructure. This was proven by the recent (Dec 5, 2012) patent victory in Europe won over their proprietary anti-apoptosis therapeutic protein, MANF, and its derivatives. A victory generally seen throughout the industry as a total vindication of the originally granted, broad claims/protections related to MANF.
Has anyone read the news letter that was released today on RBCC and the pending JV with AMBS?
I'm still here! Long and strong! AMBS!
I'm long and have been I since below .02! We all know what we own and it will bounce hard! A lot stop losses got hit today and manipulation by MM's HOLDING FOR GOLD!
Totally agree!
Wrong answer partner! We longs know what we own!
That's exactly what they are doing no doubt about it! this will sky rocket once the new has been released. Long AMBS!
Thanks for the cheapies! Weak hands out strong hands in! Got to love it!
They are trying to shake out the weak hands IMO!
The next 3 days will be exciting and rewarding for shareholders! Enjoy the ride UP! PR any day or any minute on the results! GLTA!
I would get in before you have to chase it monday!
Us longs know what we own! This is one of the best pennies out there! Holding! GO AMBS!
Tuesday's results will send this thru the clouds. Hold strong! Long AMBS!
Depends on your broker. Most have received their new shares only a few brokers have not transferred yet and should by cob today!
Anyone would be crazy to sell before Tuesday!
2 trading days left before conference! Get in while you can! This thing is going to breakout ahead! IMO!
Not with the news thats coming!
Not giving a single share of this gold mine!
Totally agree! I want to thanks those who sold me their shares at dirt cheap prices this morning!
I would advise anyone selling to get back in before jan 8th IMHO this is going to the moon in the next few days
Buy buy buy!!!
Exactly!
Shaking out weak hands! Hold bc this is going to the moon in a few days!
Agree totally! This is so promising!
Anyone would be crazy to sell once their new shares are released from their broker! Hold and see the profits continue to rise! I'm holding LONG! Jan 8th in less than a week!
52 week high coming!
HAPPY NEW YEAR AND THE BEST TO ALL! I'm off of here for the rest of this year!
I'm one of those longs and loving it!
Anyone would be crazy to sell their shares once they have access to them. This is to good to take a a small profit IMO! Hold and retire early! AMBS LONG!
Woke up this morning and I no longer have realtim or level 2 access but I am a paid subscriber.Anyone else having this issue or can tell me what to do?
Thanks! I have emailed them again and will let you know if I get an answer.
Did you email them. I did earlier today and haven't got a response as of now. Thanks